Affimed Announces Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 7, 2019
July 31 2019 - 5:00AM
Heidelberg, Germany, July 31, 2019 – Affimed
N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company
committed to giving patients back their innate ability to fight
cancer, today announced that it will host a conference call on
Wednesday, August 7, 2019 at 8:30 a.m. ET to discuss its second
quarter 2019 financial results and recent corporate
developments.
The conference call will be available via phone
and webcast. To access the call, please dial +1 917 7200 178 for
U.S. callers, or +44 (0) 203 0095710 for international callers, and
reference conference ID 9396039 approximately 15 minutes prior to
the call.
An audio webcast of the conference call can be
accessed in the “Webcasts” section on the “Investors” page of the
Affimed website at https://www.affimed.com/investors/webcasts/. A
replay of the webcast will be available on Affimed’s website
shortly after the conclusion of the call and will be archived for
30 days following the call.
About Affimed N.V.Affimed
(Nasdaq: AFMD) is a clinical stage biopharmaceutical company
committed to giving patients back their innate ability to fight
cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell
engagers to be designed for specific patient populations. The
Company is developing single and combination therapies to treat
hematologic and solid tumors. For more information, please visit
www.affimed.com.
Affimed Investor
Contact:Gregory Gin, Head of Investor RelationsE-Mail:
IR@affimed.com
Affimed Media Contact:Anca
Alexandru, Head of Communications, EU IRE-Mail:
media@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024